FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFIC | IAL OWNER | SHIP |
|------------------|------------|--------------|-----------|------|

| | OMB APPROVAL | | | | | | | |
|---|------------------------|-----------|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | |
| l | Estimated average burd | en | | | | | | |
| l | hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | | | | | (, | | | | ompany Act | | | | | | | | | |
|--|--|------|---------------|------------------|--------|--|--------|------|---|---|---|---------------|---------------------------|--|---|---|--|--|-------------|--|
| Name and Address of Reporting Person* Ventech Capital II | | | | | | 2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC EYEG] | | | | | | | | | 5. Relationship of Reportin (Check all applicable) Director Officer (give title | | | 10% C | | |
| (Last) (First) (Middle) 47 AVENUE DE L'OPERA | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/06/2016 | | | | | | | | | | w) | | below) | | |
| (Street) PARIS (City) | IO (St | | 75002 Zip) | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| | | Tabl | e I - N | on-Deriv | /ative | Seci | uritie | s Ac | quire | d, Di | sposed o | f, or E | Benefic | ially | Owne | ed | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/ | | | | | | Execution Date, /Year) if any | | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a | | | nd 5) Secu Bene Own | | icially d Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | | Reported Transaction(s) (Instr. 3 and 4) | | | | (iiisti. 4) | |
| Common Stock 06/06/20 | | | | | 2016 | 16 | | S | | 10,000 | D | \$3.26 | 684 ⁽¹⁾ | 1,641,540 | | I |) | | | |
| Common Stock 06/07/20 | | | | | 2016 | 16 | | S | | 17,000 | D | \$3.23 | 2388(2) | | 1,624,540 | |) | | | |
| Common Stock 06/08/20 | | | | | 2016 |)16 | | S | | 2,400 | D | \$3 | \$3.2 | | 1,622,140 | |) | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | vative drifty or Exercise price of Derivative Security Date (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) 8) | | | Transa Code (| | Str. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Exercisable | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares | | | | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Ow For Dire or I (I) (| nership m: ect (D) ndirect Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.21 to \$3.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.21 to \$3.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

/s/ J. Fraser Collin, attorney-infact (signed under power of attorney on behalf of Reporting Person)

06/09/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.